Nucana (NCNA) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NuCana plc has announced the discontinuation of its Phase 2 NuTide:323 study for colorectal cancer due to unlikely achievement of primary objectives, despite the treatment’s favorable safety profile. The company remains committed to cancer treatment improvement, focusing on ongoing studies such as NuTide:303 and NuTide:701, with promising data on NUC-7738 plus Pembrolizumab to be presented at the ESMO conference.
For further insights into NCNA stock, check out TipRanks’ Stock Analysis page.